Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

SELL
$2.68 - $3.22 $173,913 - $208,955
-64,893 Reduced 14.32%
388,133 $1.09 Million
Q2 2023

Aug 11, 2023

BUY
$1.78 - $3.2 $773,739 - $1.39 Million
434,685 Added 2370.02%
453,026 $1.38 Million
Q1 2023

May 18, 2023

BUY
$1.09 - $2.09 $19,259 - $36,928
17,669 Added 2629.32%
18,341 $34,000
Q1 2023

May 11, 2023

SELL
$1.09 - $2.09 $14,231 - $27,287
-13,056 Reduced 95.1%
672 $1,000
Q4 2022

Feb 13, 2023

SELL
$0.94 - $1.64 $1,297 - $2,263
-1,380 Reduced 9.13%
13,728 $14,000
Q3 2022

Nov 14, 2022

BUY
$2.3 - $5.03 $3,254 - $7,117
1,415 Added 10.33%
15,108 $40,000
Q2 2022

Aug 11, 2022

SELL
$4.51 - $9.85 $5,109 - $11,160
-1,133 Reduced 7.64%
13,693 $62,000
Q1 2022

May 11, 2022

BUY
$6.89 - $16.56 $21,290 - $51,170
3,090 Added 26.33%
14,826 $146,000
Q4 2021

Feb 10, 2022

BUY
$12.18 - $17.0 $68,841 - $96,084
5,652 Added 92.9%
11,736 $179,000
Q3 2021

Nov 12, 2021

BUY
$11.61 - $15.99 $70,635 - $97,283
6,084 New
6,084 $82,000

Others Institutions Holding TALS

About Talaris Therapeutics, Inc.


  • Ticker TALS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,995,900
  • Market Cap $109M
  • Description
  • Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, an...
More about TALS
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.